IP Library › Granted Patent US 12,661,359
Granted Patent B2
US 12,661,359 · App. 18/263,546 · Granted Jun 23, 2026

Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders

Inventor: Rebecca Taub (Villanova, PA)
Assignee: Madrigal Pharmaceuticals, Inc.
A61K31/53A61K31/505A61P3/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,661,359
App. No.
18/263,546
Granted
Jun 23, 2026
Kind
B2
Abstract

The present disclosure provides a combination therapy for treating a liver disease or disorder and/or a lipid disease or disorder in a subject in need thereof. Specifically, the combination therapy comprises administration of rosuvastatin and resmetirom to a subject in need thereof.

Claims (13)

1 . A method of treating a fatty liver disease in a human subject in need thereof, the method comprising administering to the human subject in need thereof an oral dose of 60 mg to 100 mg of resmetirom per day, wherein the human subject in need thereof is on a rosuvastatin regimen of 5 mg to 20 mg per day.

2 . The method according to claim 1 , wherein the fatty liver disease is non-alcoholic steatohepatitis (NASH).

3 . The method according to claim 2 , wherein the oral dose of resmetirom is 60 mg per day.

4 . The method according to claim 2 , wherein the oral dose of resmetirom is 80 mg per day.

5 . The method according to claim 2 , wherein the oral dose of resmetirom is 100 mg per day.

6 . The method according to claim 2 , comprising administering to the subject in need thereof a pharmaceutically acceptable oral dosage form comprising Form I resmetirom.

7 . The method according to claim 2 , wherein the rosuvastatin regimen is 10 mg per day.

8 . The method according to claim 2 , comprising administering to the human subject in need thereof a gel, a tablet, a pill, or a capsule comprising the oral dose of resmetirom.

9 . The method according to claim 2 , comprising administering to the human subject in need thereof a tablet comprising the oral dose of resmetirom.

10 . The method according to claim 3 , comprising administering to the human subject in need thereof a tablet comprising the oral dose of resmetirom.

11 . The method according to claim 4 , comprising administering to the human subject in need thereof a tablet comprising the oral dose of resmetirom.

12 . The method according to claim 5 , comprising administering to the human subject in need thereof a tablet comprising the oral dose of resmetirom.

13 . The method according to claim 6 , wherein the pharmaceutically acceptable oral dosage form is a tablet.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2026
From: TAUB, REBECCA
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 073902/0781 →
SECURITY INTEREST Recorded Jul 17, 2025
From: MADRIGAL PHARMACEUTICALS, INC.
To: LSI FINANCING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 072038/0693 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2023
From: TAUB, REBECCA
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 064451/0072 →
Continuity (2)
Provisional Application 63143977 · Feb 1, 2021
Related Publication 20240307405A1 · Sep 19, 2024
References Cited (13)
US 6858618B2 · Raza et al. · 2005 [cited by applicant]
US 7452882B2 · Haynes et al. · 2008 [cited by applicant]
US 9266861B2 · Hester et al. · 2016 [cited by applicant]
US 20200390858A1 · DePaoli et al. · 2020 [cited by applicant]
WO 2018075650A1 · 2018 [cited by applicant]
Feb. 8, 2018, Madrigal Press Release (Year: 2018). [cited by examiner]
Anonymous: “Madrigal's MGL-3196 Achieves Primary Endpoint in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)”, Drug Development & Delivery, Jan. 1, 2018, pp. 1-5. [cited by applicant]
Antonopoulos et al: “Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients”, ATHEROSCLEROSIS, vol. 184, No. 1, Jan. 1, 2006, pp. 233-234. [cited by applicant]
Harrison et al: “Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial”, The Lancet, vol. 394, No. 10213, Nov. 11, 2019, pp.… [cited by applicant]
Harrison et al: “Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial”, The Lancet, vol. 394, No. 10213, Nov. 11, 2019, sup… [cited by applicant]
Jakobsson et al,. “Potential Role of Thyroid Receptor B Agonists in the Treatment of Hyperlipidemia”, Drugs,. vol. 77,.Sep. 2, 2017, pp. 1613-1621. [cited by applicant]
Kastelein et al: “LDL cholesterol, apolipoprotein B, lipoprotein(a), apolipoprotein CIII and triglyceride lowering by MGL-3196, a thyroid hormone beta selective agonist, in a 12 week study in HeFH patients”, European He… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/014384, Apr. 22, 2022 (14 pages). [cited by applicant]